Union européenne -
français -
EMA (European Medicines Agency)
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - asthme - les médicaments pour les maladies respiratoires obstructives, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Union européenne -
français -
EMA (European Medicines Agency)
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asthme - les médicaments pour les maladies respiratoires obstructives, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
Canada -
français -
Health Canada
atectura breezhaler capsule
novartis pharmaceuticals canada inc - indacatérol (acétate d'indacatérol); furoate de mométasone - capsule - 150mcg; 80mcg - indacatérol (acétate d'indacatérol) 150mcg; furoate de mométasone 80mcg - adrenals
Canada -
français -
Health Canada
atectura breezhaler capsule
novartis pharmaceuticals canada inc - indacatérol (acétate d'indacatérol); furoate de mométasone - capsule - 150mcg; 320mcg - indacatérol (acétate d'indacatérol) 150mcg; furoate de mométasone 320mcg - adrenals
Canada -
français -
Health Canada
atectura breezhaler capsule
novartis pharmaceuticals canada inc - indacatérol (acétate d'indacatérol); furoate de mométasone - capsule - 150mcg; 160mcg - indacatérol (acétate d'indacatérol) 150mcg; furoate de mométasone 160mcg - adrenals
Union européenne -
français -
EMA (European Medicines Agency)
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asthme - les médicaments pour les maladies respiratoires obstructives, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
enerzair breezhaler 150/50/160 μg hartkapsel mit pulver zur inhalation
novartis pharma schweiz ag - indacaterolum, glycopyrronium, mometasoni-17 furoas - hartkapsel mit pulver zur inhalation - indacaterolum 150 µg ut indacateroli acetas, glycopyrronium 50 µg ut glycopyrronii bromidum, mometasoni-17 furoas 160 µg, lactosum monohydricum 24..567 mg, magnesii stearas, kapselhülle: hypromellosum, carrageenanum, kalii chloridum, e 172 (flavum), e 132, aqua purificata, cera carnauba, drucktinte: aqua purificata, e 172 (nigrum), alcohol isopropylicus, propylenglycolum, hypromellosum pro capsula. - asthma - synthetika
Canada -
français -
Health Canada
enerzair breezhaler capsule
novartis pharmaceuticals canada inc - indacatérol (acétate d'indacatérol); glycopyrronium (bromure de glycopyrronium); furoate de mométasone - capsule - 150mcg; 50mcg; 160mcg - indacatérol (acétate d'indacatérol) 150mcg; glycopyrronium (bromure de glycopyrronium) 50mcg; furoate de mométasone 160mcg - antimuscarinics antispasmodics
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
atectura breezhaler 150/80 μg poudre pour inhalation en gélule
novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - poudre pour inhalation en gélule - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.080 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
atectura breezhaler 150/160 μg poudre pour inhalation en gélule
novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - poudre pour inhalation en gélule - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.160 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika